Posted on 08/07/2010 in Medical Company Restructures Bard has announced that it has completed its move to acquire the breast cancer specialist SenoRx after purchasing all shares in the company.
The deal, which was originally announced in May 2010, has been valued at approximately $200 million (131.9 million pounds) and sees SenoRx become a part of Bard's peripheral vascular division.
SenoRx is based in the US and is responsible for a wide variety of medical devices for breast cancer applications, including the EnCor range of breast biopsy systems and the Contura balloon catheter product.
According to Bard's statement in May, the deal has been initiated in order to allow the firm to expand its business into the breast biopsy market.
Timothy Ring, chairman and chief executive officer of Bard, said: "The SenoRx acquisition represents a very compelling strategic opportunity for Bard, enabling us to provide customers leadership products across all breast biopsy and marker segments."
According to Bard's most recent financial report, the company saw a nine per cent year-on-year increase in sales during the first quarter of this year.Other news stories from 08/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
